TMX-SMX (Bactrim(R))

ApprovedSmall molecule

DDepartment of Medical Services Ministry of Public Health of Thailand

TMX-SMX (Bactrim(R)) is one of 4 small molecule programs targeting Cerebral Toxoplasmosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral ToxoplasmosisActive, not recruiting

Cerebral ToxoplasmosisApproved

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Cerebral Toxoplasmosis

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 2

1 2

Daraprim

FFondazione Matilde Tettamanti Menotti De Marchi Onlus

Phase 2

1 3

Wellcovorin

EEastern Cooperative Oncology Group

Phase 2

1 4

TMX-SMX (Bactrim(R))

DDepartment of Medical Services Ministry of Public Health of Thailand

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cerebral Toxoplasmosis1 trial

Treatment of Cerebral Toxoplasmosis in HIV/AIDS

Completed·DDepartment of Medical Services Ministry of Public Health of Thailand·Phase 4·NCT00367081·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TMX-SMX (Bactrim(R)). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TMX-SMX (Bactrim(R)) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TMX-SMX (Bactrim(R)). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Department of Medical Services Ministry of Public Health of Thailand company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: DDepartment of Medical Services Ministry of Public Health of Thailand

TMX-SMX (Bactrim(R))

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cerebral Toxoplasmosis1 trial

References

Drug Info

Quick Facts

Related News